Originally published by our sister publication Specialty Pharmacy Continuum
The Trump administration’s newly unveiled “TrumpRx” initiative—a partnership with Pfizer framed as the first step toward applying most-favored-nation (MFN) drug pricing in the United States—is being touted as a game changer in making prescription drugs more affordable.
But due to a lack of specifics on how the plan works, along with no mandate for widespread stakeholder participation, many health policy analysts argue its real-world value is limited.
The plan, detailed in a Sept. 30 White House fact sheet and subsequent Pfizer communications, was formally announced during a White House event in which President Trump appeared alongside Pfizer CEO Albert Bourla, PhD, to announce the agreement, which Dr. Bourla called “a win for American patients, a win for American leadership, and a win for Pfizer.”
“By working closely with the Administration, we are lowering costs for patients and enabling greater investment in the U.S. biopharmaceutical ecosystem by ending the days when American families alone carried the global burden of paying for innovation,” he said in a statement.
Under the deal, Pfizer would offer its drugs to state Medicaid programs at MFN-style prices and participate in a new government-run “TrumpRx” website allowing uninsured consumers to purchase certain branded drugs at discounted cash prices. (Pfizer’s press release said that the “large majority” of its primary care treatments and some specialty brands “will be offered at savings that will range as high as 85% and on average 50%.”) The administration asserted the goal is to ensure that Americans “no longer pay more than other nations” for medications.
Yet even supporters of pricing reform say that many key details remain undisclosed, and that the initiative’s reach appears narrow.
Pricing Terms Remain Confidential
“It’s hard to know how much this will really accomplish because so few details have been released,” said Juliette Cubanski, PhD, the deputy director of the Program on Medicare Policy at KFF, a nonprofit organization that provides information and analysis on health policy in the United States. “The White House and Pfizer have both suggested that many specifics—including pricing terms—will remain confidential, reportedly for proprietary reasons. Without those details, it’s impossible to assess the true scope or magnitude of savings.”
According to the administration, Pfizer will sell its products to state Medicaid programs using the lowest price available among comparably wealthy nations. But Medicaid already wields substantial negotiating leverage, said Stacie Dusetzina, PhD, a professor of health policy and Ingram Professor of Cancer Research at Vanderbilt University Medical Center, in Nashville. “Many of Pfizer’s drugs are older and have seen significant list-price increases over time, which actually gives Medicaid larger statutory rebates,” she said. “It’s entirely possible that Medicaid’s current net prices are already lower than international ones. So, this may not save much, if anything, over what Medicaid already pays.”
Pfizer’s own statement repeatedly emphasized that the deal is “voluntary,” Dr. Dusetzina pointed out, which raises further doubts about its durability. “To what degree might we expect them to retreat from certain promises if they looked like they were going to actually harm the company’s bottom line? That’s an open question,” she said.
Merith Basey, the executive director of Patients for Affordable Drugs, a national patient advocacy organization focused on lowering prescription drug prices that does not accept funding from the pharmaceutical marketplace, shared similar reservations. “The devil’s in the details, and there’s still a lot of information that is missing,” she said. “Patients in our community are extremely concerned about high drug prices, and we are encouraged to see the administration focus directly on this issue. But given the broad lack of information, it’s still unclear which drugs would be included, at what prices, and who would really benefit.”
Ms. Basey added that the plan “is really not tackling that challenge, which is at the heart of the problem we see here in the U.S.—that launch prices of new drugs are always set by pharmaceutical corporations.” She said her group would like to see broader, more systemic reforms. “Medicare negotiation is one of the most important programs to change direct pricing here in the U.S. We would like to see more drugs negotiated for people on Medicare, and we would like to see even lower prices across the board.”
She also pointed to the need for patent-reform legislation pending in Congress and warned that voluntary arrangements like TrumpRx “could be temporary at best,” adding: “We don’t know how long these prices could be lowered or if they will be for very long.”
‘Amazon-style’ Marketplace Touted
The TrumpRx website, which will launch with Pfizer as the first participating manufacturer, is designed to allow consumers to buy some branded drugs at discounted cash prices—an approach administration officials have likened to an “Amazon-style” marketplace. But experts say the model closely resembles existing efforts—most notably, Mark Cuban’s Cost Plus Drugs—and faces similar limitations.
“This approach may offer modest relief for a narrow slice of people, mainly those who are uninsured or in high-deductible plans,” Dr. Cubanski said. “But even if the discounts are significant off the list price, most patients won’t find a $600 or $3,000 drug affordable. It’s not a substitute for having insurance coverage.”
Dr. Dusetzina agreed, noting that for some drugs, patients could already find better prices elsewhere. “If you look at a product like Xeljanz [tofacitinib, Pfizer], you could actually get a lower price through GoodRx than the price listed on the TrumpRx website,” she said. “For the average consumer, this is not the best path to savings.”
Robert Andrews, CEO of the Health Transformation Alliance, a cooperative of more than 70 leading self-insured employers focused on improving healthcare quality and affordability for employees and their families, called the announcement “a welcome step toward accountability” but cautioned that “what was announced the other day isn’t going to move the needle very much,” adding that the initiative’s scope is “symbolically positive but substantively limited.”
Mr. Andrews, a former Democratic member of Congress from New Jersey who helped craft and pass the Affordable Care Act, enacted in March 2010 to lower the costs of health care, said any effort to push drugmakers toward price justification is welcome. However, TrumpRx “won’t move the needle very much,” he said, adding that the direct purchasing option “appears to be for consumers paying entirely out of pocket, not through their employer health plan, Medicare, or Medicaid. That’s a very small share of the market. Telling someone who makes $42,000 a year that they now have the right to buy a $600 drug is like saying they have the right to buy a Mercedes. They have the right—but they can’t afford it.”
Industry Optics and PBM Fallout
The announcement also sent “a powerful signal to the PBM industry,” Mr. Andrews said. “When the president stands in the Oval Office with a major drug company CEO saying, ‘We want to make it easier for consumers to buy directly,’ that’s a clear warning to pharmacy benefit managers. The big three PBMs are now thinking hard about whether they should change their business model voluntarily before regulation forces it.”
Indeed, the White House framing of TrumpRx as a move to “cut out the middlemen” and promote “price transparency” reflects longstanding criticisms of PBM rebate schemes. But experts caution that eliminating PBMs doesn’t necessarily lower overall costs—especially when manufacturers retain full control over list prices and rebate structures.
From the drugmakers’ perspective, Dr. Cubanski added, direct-to-consumer sales allow them to sidestep the rebate and formulary negotiations that have long frustrated manufacturers. “It’s an end run around the PBMs,” she said, “but it doesn’t automatically translate into affordability for patients.”
Another central limitation is scale: Pfizer is the only company currently participating. “This is one drug company making one deal,” Dr. Cubanski said. “It’s a voluntary effort, not a law or regulation, and we don’t yet know what would compel Pfizer, or any future partners, to stick with the terms.”
While Pfizer receives a three-year reprieve from threatened 100% import tariffs as part of the arrangement, the deal doesn’t bind other firms. “It’s unclear whether other manufacturers will be eager to sign similar agreements, especially when the benefits are uncertain and the details confidential,” Dr. Cubanski said.
Mr. Andrews said he would like to see the administration take a stronger stance on value-based pricing, linking payment for drugs to their demonstrated clinical and economic outcomes. “If a company says a therapy will reduce long-term medical costs, it should take some of the risk if those savings don’t materialize,” he said. “That’s where the real reform opportunity lies.”
Flawed Dynamics Remain
The experts agreed that while TrumpRx may raise awareness and create a public narrative about “action” on drug costs, it is unlikely to alter the fundamental dynamics that drive high prices in the U.S. pharmaceutical market. “It will not produce real savings for most patients,” Dr. Dusetzina said. “Maybe a handful of people in very specific scenarios could benefit, but for the average consumer, there are better options.”
Ms. Basey said the public is demanding deeper, mandatory reforms. “One in three Americans are still struggling to pay for their prescription drugs,” she said. “Americans are paying between four and eight times what other high-income countries are paying for their drugs. The vast majority of citizens are demanding Congress do a lot more.” Such reform “is incredibly popular—and incredibly urgent.”
The sources reported no relevant financial disclosures.